Neo Ivy Capital Management Invests $1.83 Million in Illumina, Inc. $ILMN

Neo Ivy Capital Management bought a new stake in Illumina, Inc. (NASDAQ:ILMN) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 19,238 shares of the life sciences company’s stock, valued at approximately $1,827,000.

Several other large investors also recently bought and sold shares of ILMN. Generali Asset Management SPA SGR grew its position in shares of Illumina by 51.6% during the third quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock worth $2,113,000 after buying an additional 7,574 shares in the last quarter. Andra AP fonden raised its holdings in Illumina by 426.3% in the second quarter. Andra AP fonden now owns 102,491 shares of the life sciences company’s stock valued at $9,779,000 after acquiring an additional 83,017 shares in the last quarter. Aaron Wealth Advisors LLC lifted its stake in Illumina by 342.6% in the third quarter. Aaron Wealth Advisors LLC now owns 10,476 shares of the life sciences company’s stock worth $995,000 after acquiring an additional 8,109 shares during the last quarter. Douglas Lane & Associates LLC grew its holdings in Illumina by 6.6% during the 3rd quarter. Douglas Lane & Associates LLC now owns 307,609 shares of the life sciences company’s stock worth $29,214,000 after acquiring an additional 18,914 shares in the last quarter. Finally, Nordea Investment Management AB grew its holdings in Illumina by 148.6% during the 3rd quarter. Nordea Investment Management AB now owns 32,657 shares of the life sciences company’s stock worth $3,024,000 after acquiring an additional 19,519 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 2.8%

Illumina stock opened at $124.62 on Friday. The company has a market capitalization of $19.05 billion, a P/E ratio of 22.87, a PEG ratio of 2.45 and a beta of 1.45. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $155.53. The stock has a 50-day simple moving average of $134.37 and a 200-day simple moving average of $119.12.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

ILMN has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Canaccord Genuity Group increased their target price on Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a report on Monday, January 26th. Barclays raised their price target on Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Evercore set a $150.00 price target on Illumina in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. lowered their price objective on Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Six analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Illumina has a consensus rating of “Hold” and an average price target of $129.69.

Insiders Place Their Bets

In other news, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the sale, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Scott M. Davies sold 323 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the sale, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This trade represents a 1.77% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.60% of the stock is owned by corporate insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.